Selective effects of electrostatic changes in the CD4 CDR-3-like loop on infection by different human immunodeficiency virus type 1 isolates

AIDS Research and Human Retroviruses

Volumn 12, Issue 11, 1996, Pages 1001-1013

  Signoret, Nathalie ^a   Blanc Zouaoui, Dominique ^b   Kwong, Peter D ^c   Sattentau, Quentin J ^a  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MUTANT PROTEIN; RECOMBINANT PROTEIN; VIRUS DNA; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE ACTIVATION; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0029781772     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.1001     Document Type: Article

References (71)

1. Sweet RA, Truneh A, and Hendrickson WA: CD4: Its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target. Curr Opin Biotechnol 1991;2:622-633.
2. Signoret N, Poignard P, Blanc D, and Sattentau QJ: Human and simian immunodeficiency viruses: Virus-receptor interactions. Trends Microbiol 1993;1:328-333.
3. Arthos J, Deen KC, Chaikin MA, Fornwald JA, Sathe G, Sattentau QJ, Clapham PR, Weiss RA, McDougal JS, Pietropaolo C, Axel R, Truneh A, Maddon PJ, and Sweet RW: Identification of the residues in human CD4 critical for the binding of HIV. Cell 1989; 57(3):469-481.
4. Chao BH, Costopoulos DS, Curiel T, Bertonis JM, Chisholm P, Williams C, Schooley RT, Rosa JJ, Fisher RA, and Maraganore JM: A 113-amino acid fragment of CD4 produced in Escherichia coli blocks human immunodeficiency virus-induced cell fusion. J Biol Chem 1989;264:5812-5817.
5. Schockmel GA, Somoza C, Davis SJ, Williams AF, and Healey D: Construction of a binding site for human immunodeficiency virus type 1 gp120 in rat CD4. J Exp Med 1992;175:301-304.
6. Simon JHM, Somoza C, Schockmel GA, Collin M, Davis SJ, Williams AF, and James W: A rat CD4 mutant containing the gp120-binding site mediates human immunodeficiency virus type 1 infection. J Exp Med 1993;177:949-954.
7. Ryu SE, Kwong PD, Truneh A, Porter TG, Arthos J, Rosenberg M, Dai XP, Xuong NH, Axel R, Sweet RW, and Hendrickson WA: Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature (London) 1990;348:419-426.
8. Wang J, Yan Y, Garrett TPJ, Liu J, Rodjers DW, Garlick RL, Terr GE, Husain Y, Reinherz EL, and Harrison SC: Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature (London) 1990;348:411-419.
9. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-415.
10. Hart TK, Kirsh R, Ellens H, Sweet RW, Lambert DM, Petteway SR Jr, Leary J, and Bugelski PJ: Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci USA 1991;88:2189-2193.
11. Kirsh R, Hart TK, Ellens H, Miller J, Pettaway SR, Lambert DM, Leary J, and Bugelski PJ: Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1. AIDS Res Hum Retroviruses 1990;6:1209-1212.
12. Moore JP, McKeating JA, Weiss RA, and Sattentau QJ: Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990;250:1139-1142.
13. Moore JP, McKeating JA, Norton WA, and Sattentau QJ: Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralisation by soluble CD4. J Virol 1991;65:1133-1140.
14. Sattentau QJ, Moore JP, Vignaux F, Traincard F, and Poignard P: Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol 1993;67:7383-7393.
15. Berger EA, Lifson JD, and Eiden LE: Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: Implications for the role of the complementarity-determining region 3-like region in membrane fusion. Proc Natl Acad Sci USA 1991;88:8082-8086.
16. Allan JS: Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science 1991;252:1322-1323.
17. Moore JP, McKeating JA, Weiss RA, Clapham PR, and Sattentau QJ: Model for receptor mediated activation of immunodeficiency viruses in viral fusion. Science 1991;252:1322-1323.
18. Moore JP, Jameson B, Weiss RA, and Sattentau QJ: The HIV-cell fusion reaction. In: Viral Fusion Mechanisms (Bentz J, ed.). CRC Press, Boca Raton, Florida, 1992, pp. 233-289.
19. Lifson JD, Hwang KM, Nara PL, Fraser B, Padgett M, Dunlop NM, and Eiden LE: Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science 1988;241:712-716.
20. Nara PL, Hwang KM, Rausch DM, Lifson JD, and Eiden LE: CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle. Proc Natl Acad Sci USA 1989;86:7139-7143.
21. Camerini D and Seed B: A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site. Cell 1990;60:747-754.
22. Truneh A, Buck D, Cassait DR, Juszczak R, Kassis S, Ryu SE, Healey D, Sweet R, and Sattentau Q: A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion. J Biol Chem 1991;266:5942-5948.
23. Corbeau P, Benkirane M, Weil R, David C, Emiliani S, Olive D, Mawas C, Serre A, and Devaux C: Ig CDR-3 like region of CD4 molecule is involved in syncytia formation but not in viral entry. J Immunol 1993;150:290-301.
24. Eiden LE and Lifson JD: HIV interactions with CD4: A continuum of conformations and consequences. Immunol Today 1992; 13:201-206.
25. Repke H, Gabuzda D, Palu G, Emmrich F, and Sodroski J: Effects of CD4 synthetic peptides on HIV type I envelope glycoprotein function. J Immunol 1992;149:1809-1816.
26. Moore JP: A monoclonal antibody to the CDR-3 region of CD4 inhibits sCD4 binding to virions of HIV-1. J Virol 1993;67: 3656-3659.
27. Broder CC and Berger EA: CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion. J Virol 1993;67(2):913-926.
28. Benkirane M, Corbeau P, Housset V, and Devaux C: An antibody that binds the immunoglobulin CDR-3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells. EMBO J 1993;12:4909-4921.
29. Benkirane M, Him M, Carriere D, and Devaux C: Functional epitope analysis of the human CD4 molecule: Antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR-3-like region of CD4. J Virol 1995;69(11): 6898-6903.
30. Langedijk JP, Puijk WC, Van Hoorn WP, and Meloen RH: Location of CD4 dimerization site explains critical role of CDR-3-like region in HIV-1 infection and T-cell activation and implies a model for complex of coreceptor-MHC. J Biol Chem 1993;268: 16875-16878.
31. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, and Wiley DC: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature (London) 1993;364:33-39.
32. Konig R, Shen X, and Germain RN: Involvement of both major histocompatibility complex class II α and β chains in CD4 function indicates a role for ordered oligomerization in T cell activation. J Exp Med 1995;182:779-787.
33. Sakihama T, Smolyar A, and Reinherz EL: Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. Proc Natl Acad Sci USA 1995;92:6444-6448.
34. Tremblay M, Meloche S, Gratton S, Wainberg MA, and Sekaly R: Association of p56lck with the cytoplasmic domain of CD4 modulates HIV-1 expression. EMBO J 1994;13:774-783.
35. Bugelski PJ, Ellens H, Hart TK, and Kirsh RL: Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: Implications for clinical trials. J Acquir Immune Defic Syndr 1991;4:923-924.
36. Folks T, et al.: Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS) associated retrovirus. Proc Natl Acad Sci USA 1985;82:4539-4543.
37. Markowitz D, Goff S, and Bank A: A safe packaging line for gene transfer Separating viral genes on two different plasmids. J Virol 1988;62:1120-1124.
38. Miller AD and Buttimore C: Redesigning of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986;6:2895-2902.
39. Fisher AG, Collati E, Ratner L, Gallo RC, and Wong-Staal F: A molecular clone of HTLV III with biological activity. Nature (London) 1985;316:262-265.
40. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, and Safai B: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-503.
41. Shaw GM, Hahn BH, Arya SK, Groopman JE, Gallo RC, and Wong-Staal F: Molecular characterization of human T cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984;226:1165-1171.
42. Levy JA, Hoffman AD, Kramer SM, Landis JA, and Shimabukuro JM: Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984;225:840-842.
43. Courcoul M, Patience C, Rey F, Blanc D, Harmache A, Sire J, Vigne R, and Spire B: Peripheral blood mononuclear cells produce normal amounts of defective VIF-human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol 1995;69:2068-2074.
44. Healey D, Wanda L, Moore JP, McDougal JS, Moore MJ, Estess P, Buck D, Kwong PD, Beverley PCL, and Sattentau QJ: Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med 1990;172:1233-1242.
45. Healey DG, Dianda L, Buck D, Schroeder K, Truneh A, Sattentau QJ, and Beverley PCL: A highly selected panel of anti-CD4 antibodies fails to induce anti-idiotypic antisera mediating human immunodeficiency virus neutralization. Eur J Immunol 1991;21: 1491-1498.
46. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, Williams C, and Chisholm P: Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion, J Immunol 1992;149:1779-1787.
47. Moore JP, Sattentau QJ, Klasse PJ, and Burkly LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992;66:4784-4793.
48. Sattentau QJ, Arthos J, Deen K, Hanna N, Healey D, Beverley PC, Sweet R, and Truneh A: Structural analysis of the human immun-odeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes. J Exp Med 1989;170: 1319-1334.
49. Carrel S, Moretta A, Pantaleo G, Tambussi G, Isler P, Perussia B, and Cerottini JC: Stimulation and proliferation of CD4 peripheral blood T lymphocytes by an anti-CD4 monoclonal antibody. Eur J Immunol 1988;18:333-339.
50. Davis SJ, Schockmel GA, Somoza C, Buck DW, Healey DG, Rieber EP, Reiter C, and Williams AF: Antibody and HIV-1 gp120 recognition of CD4 undermines the concept of mimicry between antibodies and receptors. Nature (London) 1992;358:76-79.
51. Kinney-Thomas E, Weber JN, McClure J, Clapham PR, Singhal MC, Shriver MK, and Weiss RA: Neutralizing monoclonal antibodies to the AIDS virus. AIDS 1988;2:25-29.
52. Prince AM, Horowitz B, Baker L, Shulman RW, Ralph H, Valinski J, Cundell A, Brotman B, Boehle W, Rey F, Piet M, Reesink H, Lelie N, Tersmette M, Miedema F, Barbosa L, Nemo G, Nastala CL, Allan JS, Lee DR, and Eichberg JW: Failure of a human immunodeficiency virus (HIV) immune globin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci USA 1988;85:6944-6948.
53. Gorga JC, Horegisi Y, Johnson DR, Raghupathy R, and Strominger JL: Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. J Biol Chem 1987;262:16087-16094.
54. Sambrook J, Fritsch EF, and Maniatis T: Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.
55. Maddon PJ, McDougal JS, Clapham PR, Dalgleish AG, Jamal S, Weiss RA, and Axel R: HIV infection does not require endocytosis of its receptor, CD4. Cell 1988;54:865-874.
56. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, and Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986;47:333-348.
57. Moore JP, McKeating JA, Jones IM, Stephens PE, Clements G, and Weiss RA: Characterization of recombinant gp120 and gp160 from HIV-1: Binding to monoclonal antibodies and sCD4. AIDS 1990;4:307-315.
58. Haigwood NL, Nara PL, Brooks E, Van Nest GA, Ott G, Higgins KW, Dunlop N, Csandella CJ, Eichberg JW. and Steimer KS: Native but not denatured recombinant human immunodeficiency virus type-1 gp120 generates broad-spectrum neutralizing anti-bodies in baboons. J Virol 1992;66:172-182.
59. Ponder JW and Richards FM: Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. J Mol Biol 1987;193:775-791.
60. Brand D, Srinivasan K, and Sodroski J: Determinants of human immunodeficiency virus type 1 entry in the CDR-2 loop of the CD4 glycoprotein. J Virol 1995;69:166-171.
61. Nicholls A, Sharp KA, and Honig B: Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 1991;11:281-296.
62. Kalyanaraman VS, Rausch DM, Osborne J, Padgett M, Hwang KM, Lifson JD, and Eiden LE: Evidence by peptide mapping that the region CD4 (81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation. J Immunol 1990;145:4072-4078.
63. Lifson JD, Rausch DM, Kalyanaraman VS, Hwang KM, and Eiden LE: Synthetic peptides allow discrimination of structural features of CD4 (81-92) important for HIV-1 infection versus HIV-1-induced syncitium formation. AIDS Res Hum Retroviruses 1991;7: 521-527.
64. Meshcheryakova D, Andreev S, Tarasova S, Sidorova M, Vafina M, Komilaeva G, Karamov E, and Khaitov R: CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. Mol Immunol 1993;30:993-1001.
65. Ohki K, Kimura T, Ohmura K, Morikawa Y, Jones IM, Azuma I, and Ikuta K: Monoclonal antibodies to a CD4 peptide derivative which includes the region corresponding to an immunoglobulin CDR3; Evidence of the involvement of pre-CDR3-related region in HIV-1 and host cell interaction. Mol Immunol 1992;29:1391-400.
66. Shapira-Nahor O, Golding A, Vujcic LK, Resto-Ruiz S, Fields RL, and Robey FA: CD4 derived synthetic peptide blocks the binding of HIV-1 gp120 to CD4-bearing cells and prevent HIV-1 infection. Cell Immunol 1990;128:101-117.
67. Cordonnier A, Montagnier L, and Emmerman M: Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature (London) 1989;340:571-574.
68. Olshersky U, Helseth E, Furman C, Li J, Haseltine W, and Sodroski J: Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990;64:5701-5707.
69. Moore JP, Sattentau QJ, Wyatt R, and Sodroski J: Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol 1994;68: 469-484.
70. McDonnel JM, Blank KJ, Rao PE, and Jameson BA: Direct involvement of the CDR-3-like domain of CD4 in T helper cell activation. J Immunol 1992;149:1626-1630.
71. Jameson BA, McDonnel JM, Marini JC, and Korngold R: A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature (London) 1994;368:744-746.